{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:11:00Z","timestamp":1779387060722,"version":"3.53.1"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>A recent meta-analysis demonstrated the efficacy of stem cell therapy for ischemic stroke; however, its cost-effectiveness has not yet been sufficiently explored. Building on the clinical data from that meta-analysis, we aimed to evaluate the cost-effectiveness of the administration of mesenchymal stem cells for acute and subacute ischemic stroke compared with the standard of care. A cost-utility analysis was performed via simulation by using a Markov model. The participants were patients treated for acute or subacute ischemic stroke in hospitals in Japan. Stem cell therapy plus the standard of care (the stem cell group) was compared with the standard of care alone (the control group). The time horizon was 10 years. The primary outcome was the cost of stem cell therapy when the incremental cost-effectiveness ratio, calculated based on costs and quality-adjusted life years for both groups, was 5 million yen\/quality-adjusted life year, the reference value in the cost-effectiveness evaluation in Japan. Efficacy data are obtained from the meta-analysis. Base-case analysis was performed using the most plausible or average values for all input parameters. Scenario and sensitivity analyses were also conducted. In the base case, the stem cell therapy cost when the incremental cost-effectiveness ratio was 5 million yen\/quality-adjusted life year was $,3,746 from the public health payer\u2019s perspective and $5,157 from the public healthcare and long-term care\u00a0payer\u2019s\u00a0perspective. The scenario and sensitivity analyses supported the cost-effectiveness of stem cell therapy for acute and subacute ischemic stroke. This study provides threshold costs of stem cell therapy at which it becomes cost-effective for acute and subacute ischemic stroke. These results may support rational pricing strategies for stem cell therapy and facilitate its seamless integration into clinical practice.<\/jats:p>","DOI":"10.1371\/journal.pone.0349756","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:25:56Z","timestamp":1779384356000},"page":"e0349756","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of stem cell therapy versus standard of care for acute and subacute ischemic stroke"],"prefix":"10.1371","volume":"21","author":[{"given":"Soichiro","family":"Takamiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Morii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-1726","authenticated-orcid":true,"given":"Toshiya","family":"Osanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3779-3628","authenticated-orcid":true,"given":"Kazuki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiro","family":"Houkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"5","key":"pone.0349756.ref001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1474-4422(19)30034-1","article-title":"Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Stroke Collaborators","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"pone.0349756.ref002","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5551\/jat.64753","article-title":"Effect of Hospital Arrival Time on Functional Prognosis of Stroke Patients: Japan Stroke Data Bank Over 20 Years","volume":"32","author":"T Omae","year":"2025","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"pone.0349756.ref003","doi-asserted-by":"crossref","first-page":"606","DOI":"10.25122\/jml-2021-0361","article-title":"The economic burden of stroke: a systematic review of cost of illness studies","volume":"14","author":"S Strilciuc","year":"2021","journal-title":"J Med Life"},{"issue":"10029","key":"pone.0349756.ref004","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials","volume":"387","author":"M Goyal","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"pone.0349756.ref005","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jama.2016.13647","article-title":"Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis","volume":"316","author":"JL Saver","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"pone.0349756.ref006","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1007\/s00415-020-10138-5","article-title":"Mesenchymal stem cell therapy for ischemic stroke: A look into treatment mechanism and therapeutic potential","volume":"268","author":"J Li","year":"2021","journal-title":"J Neurol"},{"issue":"5","key":"pone.0349756.ref007","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/STROKEAHA.118.018287","article-title":"Intravenous Cellular Therapies for Acute Ischemic Stroke","volume":"49","author":"RW Mays","year":"2018","journal-title":"Stroke"},{"issue":"2","key":"pone.0349756.ref008","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000086518","article-title":"Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study","volume":"20","author":"SI Savitz","year":"2005","journal-title":"Cerebrovasc Dis"},{"issue":"16","key":"pone.0349756.ref009","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1073\/pnas.2000690117","article-title":"Activity in grafted human iPS cell-derived cortical neurons integrated in stroke-injured rat brain regulates motor behavior","volume":"117","author":"S Palma-Tortosa","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0349756.ref010","doi-asserted-by":"crossref","first-page":"21214","DOI":"10.1038\/s41598-025-04405-6","article-title":"Efficacy and safety of stem cell therapy for acute and subacute ischemic stroke: a systematic review and meta-analysis","volume":"15","author":"T Osanai","year":"2025","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0349756.ref011","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1159\/000337765","article-title":"Societal value of stem cell therapy in stroke--a modeling study","volume":"33","author":"J Svensson","year":"2012","journal-title":"Cerebrovasc Dis"},{"issue":"2","key":"pone.0349756.ref012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/MRR.0000000000000108","article-title":"Six-month functional recovery of stroke patients: a multi-time-point study","volume":"38","author":"KB Lee","year":"2015","journal-title":"Int J Rehabil Res"},{"issue":"8","key":"pone.0349756.ref013","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.05.020","article-title":"Cost Effectiveness of Drive and Retrieve System in Hokkaido for Acute Ischemic Stroke Patient Treatment Using Geographic Information System","volume":"28","author":"Y Morii","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"2","key":"pone.0349756.ref014","article-title":"Mechanical thrombectomy in patients with acute ischemic stroke: a cost-utility analysis","volume":"4","author":"X Xie","year":"2016","journal-title":"CMAJ Open"},{"issue":"1","key":"pone.0349756.ref015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12962-023-00421-3","article-title":"Cost-effectiveness of seven-days-per-week rehabilitation schedule for acute stroke patients","volume":"21","author":"Y Morii","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"pone.0349756.ref016","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","article-title":"Development of an Official Guideline for the Economic Evaluation of Drugs\/Medical Devices in Japan","volume":"20","author":"T Shiroiwa","year":"2017","journal-title":"Value Health"},{"key":"pone.0349756.ref017","author":"Yahoo Japan Corporation"},{"issue":"1","key":"pone.0349756.ref018","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/1753-0407.12384","article-title":"Projection of prediabetes and diabetes population size in Singapore using a dynamic Markov model","volume":"9","author":"LY Wong","year":"2017","journal-title":"J Diabetes"},{"key":"pone.0349756.ref019","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/COPD.S181194","article-title":"Cost-effectiveness of physical activity in the management of COPD patients in the UK","volume":"14","author":"M Ramos","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"pone.0349756.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187050","article-title":"Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial","volume":"12","author":"C Cassarly","year":"2017","journal-title":"PLoS One"},{"key":"pone.0349756.ref021","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1747493019830587","article-title":"Cost-utility analysis of mechanical thrombectomy between 6 and 24\u2009h in acute ischemic stroke","volume":"15","author":"E Pizzo","year":"2019","journal-title":"Int J Stroke"},{"issue":"2","key":"pone.0349756.ref022","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/aian.AIAN_384_20","article-title":"Stem Cell Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"A Kumar","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"issue":"7","key":"pone.0349756.ref023","article-title":"Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke","volume":"96","author":"J-W Chung","year":"2021","journal-title":"Neurology"},{"key":"pone.0349756.ref024","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221083863","article-title":"Final Results of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial","volume":"31","author":"E de Celis-Ruiz","year":"2022","journal-title":"Cell Transplant"},{"issue":"2","key":"pone.0349756.ref025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1474-4422(22)00526-9","article-title":"Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial","volume":"22","author":"F Moniche","year":"2023","journal-title":"Lancet Neurol"},{"issue":"12","key":"pone.0349756.ref026","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1177\/0271678X231202594","article-title":"Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke","volume":"43","author":"K Niizuma","year":"2023","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"pone.0349756.ref027","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jamaneurol.2023.5200","article-title":"Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2\/3 TREASURE Randomized Clinical Trial","volume":"81","author":"K Houkin","year":"2024","journal-title":"JAMA Neurol"},{"issue":"2","key":"pone.0349756.ref028","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/stcltm\/szad080","article-title":"A Randomized, Placebo-Controlled, Phase II Trial of Intravenous Allogeneic Non-HLA Matched, Unrelated Donor, Cord Blood Infusion for Ischemic Stroke","volume":"13","author":"DT Laskowitz","year":"2024","journal-title":"Stem Cells Transl Med"},{"issue":"5","key":"pone.0349756.ref029","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S1474-4422(17)30046-7","article-title":"Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"16","author":"DC Hess","year":"2017","journal-title":"Lancet Neurol"},{"key":"pone.0349756.ref030","volume-title":"Japan stroke data bank 2015","author":"S Kobayashi","year":"2015"},{"key":"pone.0349756.ref031","unstructured":"Statistics Bureau of Japan. Statistics of Japan, Consumer Price Index. https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&toukei=00200573"},{"issue":"4","key":"pone.0349756.ref032","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2176\/nmc.52.175","article-title":"Medical care for chronic-phase stroke in Japan","volume":"52","author":"N Hattori","year":"2012","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"4","key":"pone.0349756.ref033","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/jnnp.69.4.487","article-title":"Are the modified \u201csimple questions\u201d a valid and reliable measure of health related quality of life after stroke? United Kingdom Collaborators in the International Stroke Trial","volume":"69","author":"P Dorman","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"pone.0349756.ref034","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3174\/ajnr.A5586","article-title":"Randomized Assessment of the Safety and Efficacy of Intra-Arterial Infusion of Autologous Stem Cells in Subacute Ischemic Stroke","volume":"39","author":"V Bhatia","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"pone.0349756.ref035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/sctm.18-0012","article-title":"Autologous Endothelial Progenitor Cells Transplantation for Acute Ischemic Stroke: A 4-Year Follow-Up Study","volume":"8","author":"J Fang","year":"2019","journal-title":"Stem Cells Transl Med"},{"key":"pone.0349756.ref036","first-page":"82","article-title":"Cost of illness after stroke","volume":"21","author":"M Yamaga","year":"2023","journal-title":"J Int Univ Health Welfare"},{"key":"pone.0349756.ref037","unstructured":"Japan Ministry of Health Labour and Welfare. Survey of Long-term Care Benefit Expenditures. https:\/\/www.mhlw.go.jp\/toukei\/list\/45-1.html"},{"issue":"6","key":"pone.0349756.ref038","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/stem.430","article-title":"A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke","volume":"28","author":"JS Lee","year":"2010","journal-title":"Stem Cells"},{"issue":"12","key":"pone.0349756.ref039","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1161\/STROKEAHA.114.007028","article-title":"Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial","volume":"45","author":"K Prasad","year":"2014","journal-title":"Stroke"},{"issue":"2","key":"pone.0349756.ref040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/CIRCULATIONAHA.117.030659","article-title":"A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke)","volume":"139","author":"SI Savitz","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"pone.0349756.ref041","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s12975-020-00787-z","article-title":"Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial","volume":"11","author":"A Jaillard","year":"2020","journal-title":"Transl Stroke Res"},{"key":"pone.0349756.ref042","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010814-124649","article-title":"The ethics and economics of pharmaceutical pricing","volume":"55","author":"S Parker-Lue","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"pone.0349756.ref043","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jval.2024.01.006","article-title":"Drug Pricing, Patient Welfare, and Cost-Effectiveness Analysis","volume":"27","author":"P van Baal","year":"2024","journal-title":"Value Health"},{"issue":"5","key":"pone.0349756.ref044","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/qjmed\/hcv150","article-title":"Orphan drugs: expensive yet necessary","volume":"109","author":"HI Hyry","year":"2016","journal-title":"QJM"},{"key":"pone.0349756.ref045","unstructured":"Nipro Corporation. STEMIRAC frequently asked questions. https:\/\/med.nipro.co.jp\/reg_stemirac_qa Accessed 2026 February 23."},{"key":"pone.0349756.ref046","volume-title":"World Population Prospects 2022: Summary of Results","year":"2022"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:26:04Z","timestamp":1779384364000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349756"}},"subtitle":[],"editor":[{"given":"Nazmul","family":"Haque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349756","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}